Cardium Therapeutics Generx Presentation January 2013
Cardium Therapeutics Wins Patents Rights, Settles Competition with Boston Scientific
Five Regenerative Medicine Companies Worthy of Portfolio Addition
EC Approval of Glybera A Significant Industry Milestone in Gene Therapy
Commenting on the October 25 approval by the European Commission for its gene therapy, Glybera®, Dutch biotech company uniQure said Monday it plans to start selling Glybera in Europe by mid-2013 and predicted a boom of similar therapies. The EC approval marks Glybera as the first gene therapy to be approved in the Western world.
“We believe that after Glybera’s approval gene therapy is at the beginning of a period of rapid growth similar to the development of the antibody business in the last decade,” said Joern Aldag, Chief Executive Officer at uniQure.
Equities Pounded on Friday, Erase Gains from the Week
After triple digit gains on Thursday and a better-than expected jobs report Friday morning, stocks turned south and erased all, or nearly all gains, for the week as caution ruled ahead of Tuesday’s presidential election. A pre-market jobs report initially buoyed markets to at least keep trading relatively flat until the glee subsided about the employment picture and gave way to nervousness and risk aversion that will probably remain consistent until the final votes are tallied.
Cardium Therapeutics, Inc. (CXM) Acquisition of To Go Brands Further Taps Growing Supplements Market
Late in September, a comprehensive report by Global Industry Analysts, Inc. stated that the global nutraceutical market will cross $243 Billion by 2015, “owing to consumer desire for leading a healthy life and increasing scientific evidence supporting health foods.”
The research firm also attributes the strong growth rate to an aging population and rising healthcare costs as catalysts for the neutraceutical industry that it calls “one of the brightest spots in a global market suffering from its worst economic crisis.”
Cardium Therapeutics Investor Presentation with To Go Brands Acquisition
Updated Cardium Therapeutics (NYSE MKT: CXM) Investor Presentation including the acquisition of To Go Brands that was announced on October 1, 2012.
The link provided is for SlideShare. The presentation can also be found on the Cardium Therapeutics website at: http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations